Could ReWalk Robotics Ltd. (RWLK) Go Up After Reaching 52-Week Low?

July 16, 2018 - By Robert Shackelford

ReWalk Robotics Ltd. (NASDAQ:RWLK) Logo

The stock of ReWalk Robotics Ltd. (NASDAQ:RWLK) hit a new 52-week low and has $0.74 target or 9.00 % below today’s $0.81 share price. The 5 months bearish chart indicates high risk for the $28.13 million company. The 1-year low was reported on Jul, 16 by Barchart.com. If the $0.74 price target is reached, the company will be worth $2.53M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock.

The stock decreased 11.73% or $0.1079 during the last trading session, reaching $0.8121. About 533,205 shares traded or 236.02% up from the average. ReWalk Robotics Ltd. (NASDAQ:RWLK) has declined 14.29% since July 16, 2017 and is downtrending. It has underperformed by 26.86% the S&P500.

Analysts await ReWalk Robotics Ltd. (NASDAQ:RWLK) to report earnings on August, 2. They expect $-0.18 EPS, up 37.93 % or $0.11 from last year’s $-0.29 per share. After $-0.18 actual EPS reported by ReWalk Robotics Ltd. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes exoskeletons for wheelchair-bound individuals with mobility impairments or other medical conditions. The company has market cap of $28.13 million. The firm offers ReWalk Personal for everyday use to paraplegic individuals at home and in their communities; and ReWalk Rehabilitation for exercise and therapy used in hospitals and rehabilitation centers in the United States and Europe. It currently has negative earnings. ReWalk Robotics Ltd. markets and sells its products directly to institutions and individuals, as well as through third-party distributors.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.